EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 113 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR 癌症可以在家族成员中被遗传吗？ October 13, 2020 Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... January 7, 2021 Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September August 27, 2025 Survivorship and Immune Checkpoint Inhibitors July 21, 2020 Load more HOT NEWS 2020 round-up: Our biggest cancer stories of the year 6 highlights from our Black in Cancer conference Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO... News digest – naked mole-rats, junk food deals, ovarian cancer drug...
